Developing Pharma-Grade Medical Cannabis in Europe
This Aura Health Inc. profile is part of a paid investor education campaign.*
Aura Health Inc. (CSE:BUZZ) is building a vertically-integrated cannabis business focused on Europe and Israel. The company owns 80 percent of Pharmadrug, a German medical cannabis distributor with a Schedule I EU narcotics license, allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. Aura Health also owns a convertible note convertible into 54 percent of the outstanding equity of HolyCanna Ltd., a cultivation and nursery license holder in Israel, and has a binding LOI to purchase 57 percent of CannabiSendak Ltd., the builder of a network of dispensaries in Israel. Additionally, through significant extraction IP, Aura Health is dedicated to building a high-margin, downstream business of end-user products.
A Focus on Europe and Israel
In May 2019, Aura Health acquired an 80 percent equity interest in Production GmbH, a German medical cannabis distributor with a Schedule I European Union narcotics license. The allows for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU.Pharmadrug has a current allocation of medical cannabis through the German regulator sourced from Netherlands. In addition, the company has a multi-year supply agreement in place with FSD Pharma Inc. (CSE:HUGE).
Aura Health secured a 54 percent stake in HolyCanna Ltd., an Israel-based company with a cultivation and sales license. HolyCanna is developing an initial 60,000-square-foot greenhouse facility, with the ability to expand across an additional 325,000 square feet.
Aura Health has entered into a binding LOI to acquire a 57 percent of CannabiSendak Ltd., an Israeli cannabis company founded by Israeli cannabis icon and activist Shlomi Sendak. The company plans to establish licensed medical cannabis dispensaries throughout Israel. The first launch will be a high-profile dispensary in Tel Aviv featuring a café, patient consultation offerings, and medical professionals on site.
Aura Health plans to grow its distribution platform beyond Germany into other EU countries. Pharmadrug is a Schedule I Narcotics distributor, allowing the German business to export GMP medical cannabis to other EU countries as those countries legalize cannabis.
Aura Health Company Highlights
- Aura Health is a pure-play on the European cannabis market, which is expected to be the biggest consumer of cannabis in the world with more than 740 million people.
- The company owns 80 percent of Pharmadrug, one of 15 holders of a Class I narcotics license to import and distribute medical cannabis in Germany and anywhere in EU.
- Strategic investments in Israel from seed-to-sale.
- Upside in the high margin, downstream extraction space.
Aura Health’s Extraction Expertise
As part of a partnership with Nutritional High (CSE:EAT,OTCQB:SPLIF,FWB:2NU), Aura Health has access to cannabis extract expertise and the ability to leverage Nutritional High’s proprietary product development approach including:
- Proprietary techniques for infusing products with THC or CBD
- Short-path distillation techniques and machinery that ensures potency
- Product development capabilities for extracts, tablets, vapes and edible products
- Experts that specialize in different aspects across the seed-to-sale supply chain for cannabis
The Israeli Cannabis Market
Israel has been a pioneer in cannabis R&D for decades, making use of its global leadership in agricultural technology. In the early 1990s, a medical cannabis program was implemented to help cancer patients with pain related issues. Today, Israel has more than 50,000 licensed medical cannabis patients, which is one of the highest per capita rates in the world, as well as a growing number of doctors licensed to prescribe cannabis.
The country’s new medical regime began in April 2019 incorporating new reforms for the market, including a pilot program for new pharmacies and dispensaries as well as a training program for doctors which is gaining popularity. In the new regime, prescriptions do not require regulatory approval.
In January 2019, the Israeli government announced a new law, approving the export of Israeli-grown cannabis to the global market. The law makes Israel the third country in the world, after Canada and the Netherlands, to approve export of medicinal cannabis. The primary export market is expected to be in the EU. This can have benefits for Aura Health as the company continues to grow its distribution platform in Germany and into the rest of the EU.
Aura Health’s Management Team
Daniel Cohen, CFA — CEO
Daniel has over 20 years of capital markets experience, most recently spending several years as Head of Sales at Beacon Securities. During this time, Daniel successfully financed many public cannabis companies.
Keith Li, CPA — CFO
Keith has over 10 years of experience in public accounting and the private sector. His specialties include audit and assurance, corporate accounting, financial reporting, and regulatory compliance services.
Howard Brass, CFA — COO
Howard has nearly a decade of capital markets experience and spent several years leading the restructuring, growth, and sale of Cliplight Manufacturing Company to private equity firm The Jordan Company. Mr. Brass holds an HBA from the Richard Ivey School of Business and is a CFA charterholder.
David Posner — Chairman
David has long been an active player in the public cannabis sector. David is the founder and chairman of Nutritional High (EAT.CN) and played an active role in founding Tinley (TNY.CN), Lineage Grow (BUDD.CN), and Xanthic Biopharma (XTHC.CN).
*Disclaimer: The profile provides information which was sourced and approved by Aura Health (CSE:BUZZ)in order to help investors learn more about the company. Aura Health is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on Investingnews.com and channel newsletters.
The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.
INN does not provide investment advice and the information on Investingnews.com profile should not be considered a recommendation to buy or sell any security.
INN does not endorse or recommend the business, products, services or securities of any company profiled.
Readers should conduct their own research for all information publicly available concerning the company.